YM Biosciences said, "YM has been advised by Daiichi Sankyo Co., Ltd., CIMYM's sub-licensee for nimotuzumab in Japan, that they are evaluating the drug in a Phase II gastric cancer program together with Kuhnil Pharma Co. Ltd., CIMYM's sub-licensee in South Korea, and in a Phase II non-small cell lung cancer program. YM has been advised by Oncoscience AG, CIMYM's sub-licensee for Europe, that they are evaluating nimotuzumab in Phase III glioma and pancreatic cancer programs. YM has been advised by Innogene Kalbiotech PTE Ltd., a CIMYM sub-licensee, that they are evaluating nimotuzumab in Phase II and III head and neck cancer programs and a Phase II cervical cancer program."
America has no tolerance for wealthy people griping about their financial woes. But they have concerns too.